Bait Bakfar Ltd (TLV:BKFR)
Israel · Delayed Price · Currency is ILS · Price in ILA 1,546.00
-6.00 (-0.39%)
Aug 28, 2025, 5:24 PM IDT
Bait Bakfar Revenue
Bait Bakfar had revenue of 27.31M ILS in the quarter ending June 30, 2025, with 6.84% growth. This brings the company's revenue in the last twelve months to 106.25M, up 5.18% year-over-year. In the year 2024, Bait Bakfar had annual revenue of 103.40M with 4.34% growth.
Revenue (ttm)
106.25M
Revenue Growth
+5.18%
P/S Ratio
10.18
Revenue / Employee
468.04K
Employees
227
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.40M | 4.30M | 4.34% |
| Dec 31, 2023 | 99.10M | 6.11M | 6.58% |
| Dec 31, 2022 | 92.99M | 7.60M | 8.90% |
| Dec 31, 2021 | 85.39M | 944.00K | 1.12% |
| Dec 31, 2020 | 84.45M | -404.00K | -0.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 56.02B |
| Danel (Adir Yeoshua) | 2.84B |
| Kamada | 571.15M |
| BrainsWay | 155.27M |
| SofWave Medical | 234.12M |
| Novolog (Pharm-Up 1966) | 2.09B |
| Ilex Medical | 922.54M |
| InterCure | 238.85M |